Tislelizumab for untreated Hodgkin lymphoma when chemo isn’t suitable
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of classical Hodgkin lymphoma that was newly found
- You have never had treatment for Hodgkin lymphoma before
- You are age 65 or older and standard chemotherapy isn’t suitable for you due to other health problems
- Your lymphoma can be measured on scans (PET-avid lymph nodes plus a measurable node lesion)
- You are well enough to do daily activities (ECOG performance status 0 to 2)
- Your blood counts and organs (kidneys, liver, etc.) are strong enough for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether you can treat early-stage Hodgkin lymphoma with chemotherapy while avoiding radiation. It may help reduce radiation-related side effects if the treatment controls the cancer effectively.
This trial tests adding tislelizumab (an immune medicine) to standard first-line chemotherapy for people age 60 and older with newly diagnosed classic Hodgkin lymphoma. The goal is to improve how well treatment works while adapting the plan for older adults.
This trial studies whether adding atezolizumab to a chemotherapy-type treatment (the BEGEV regimen) can shrink Hodgkin lymphoma that has come back or did not respond. It may help people who have only had one prior whole-system (systemic) treatment and can still receive stem cell transplant (ASCT).
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
This trial tests a new combination of two drugs (IMM01 and Tiselizumab) for people with classical Hodgkin lymphoma that has stopped responding to standard immunotherapy. The goal is to see if this combination works better than standard chemotherapy options your doctor might choose.
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.